Tongling Jieya Biologic Technology's declining ROCE and sale...

Tongling Jieya Biologic Technology's declining ROCE and sales trends, despite employing more capital than five years ago, are concerning. The market reflects this with a 16% stock depreciation over the last year. Considering these trends, exploring other investment options may be advisable.